Lyell Immunopharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
LYEL$14.86-0.9%Stored close · as of Nov 6, 2026
What changed in Management’s Discussion and Analysis?
Read the current filingComparison unavailable
We could not identify this Item in the current filing’s readable text.
Earlier comparable report: 10-K, period ended 2024-12-31, filed 2025-03-11. Read that report
Unavailable is not the same as unchanged.